Classical 3+3 design versus "accelerated titration designs": Analysis of 270 phase 1 trials investigating anti-cancer agents

Investigational New Drugs

Volumn 27, Issue 6, 2009, Pages 552-556

  Penel, Nicolas ^a   Isambert, Nicolas ^c,d   Leblond, Pierre ^a   Ferte, Charles ^a   Duhamel, Alain ^b   Bonneterre, Jacques ^a,e  

^a CENTRE OSCAR LAMBRET   (France)

^b UNIV LILLE   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

^e UNIV LILLE   (France)

Author keywords

Accelerated titration design; Dose escalation; Method; Phase I clinical trial

Indexed keywords

ANTINEOPLASTIC AGENT;

ACCELERATED TITRATION DESIGN; ANALYTIC METHOD; ANALYTICAL PARAMETERS; ARTICLE; CLASSICAL 3+3 DESIGN; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFICACY; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; NEOPLASMS; RESEARCH DESIGN;

EID: 70450273499     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9213-5     Document Type: Article

References (13)

1. CM Booth AH Calvert G Giaccone MW Lobbezoo LK Seymour EA Eisenhauer Task Force on Methodology for the Development of Innovative Cancer Therapies 2008 Eur J Cancer 44 19 24 10.1016/j.ejca.2007.07.034 1:CAS:528:DC%2BD2sXhsVOrurvP 17890079 (Pubitemid 350256933)
2. A Morabito E Di Maio N Normanno F Perrone 2006 Methodology of clinical trials with new molecular-targeted agents: where do we stand? Ann Oncol 17 S7 vii128 vii131 10.1093/annonc/mdl965 16760275 (Pubitemid 43985193)
3. MJ Ratain R Mick R Schilsky, et al. 1993 Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents J Natl Cancer Inst 85 1637 1643 10.1093/jnci/85.20.1637 1:STN:280:DyaK2c%2Fhs1Klsw%3D%3D 8411243
4. R Simon B Friedlin LV Rubinstein SG Arbuck J Collins MC Christian 1997 Accelerated titration designs for phase I clinical trials in oncology J Natl Cancer Inst 89 1138 1147 10.1093/jnci/89.15.1138 1:CAS:528:DyaK2sXls1WnurY%3D 9262252
5. J Verweij 2008 No risk, no fun: challenges for the oncology phase I clinical trial time-performance Eur J Cancer 44 2600 2607 10.1016/j.ejca.2008. 07.043 18951015
6. N Penel M Vanseymortier ME Bonneterre S Clisant E Dansin Y Vendel R Beuscart J Bonneterre 2008 Prognostic factors among cancer patients with good performance status screened for phase I trials Invest New Drugs 26 53 58 10.1007/s10637-007-9088-x 17891337
7. G Decoster G Stein EE Holdener 1990 Response and toxic deaths in phase I clinical trials Ann Oncol 1 175 181 1:STN:280:DyaK3M%2FosVaktQ%3D%3D 2148104
8. DD Von Hoff J Turner 1991 Response rates, duration of response and dose response effects in phase I studies Invest New Drugs 9 115 121
9. T Bachelot I Ray-Coquard G Catimel, et al. 2000 Multivariate analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials Ann Oncol 11 151 156 10.1023/A:1008368319526 1:STN:280:DC%2BD3c3it1ertw%3D%3D 10761748 (Pubitemid 30148727)
10. CK Daugherty HJ Ratain E Grochowski C Stocking E Kodish, et al. 1995 Perceptions of cancer patients and their physicians involved in phase I trials J Clin Oncol 13 1062 1:STN:280:DyaK2M3ls12htw%3D%3D 7738612
11. M Agrawal EJ Emmanuel 2003 Ethics of phase I oncology studies: re-examining the arguments and the data JAMA 290 1075 1082 10.1001/jama.290.8. 1075 12941681 (Pubitemid 37430449)
12. TG Roberts BH Goulart SC Stallings, et al. 2004 Trends in the risk and benefits to patients with participating in phase I clinical trials JAMA 292 2130 2140 10.1001/jama.292.17.2130 1:CAS:528:DC%2BD2cXpsVKksbY%3D 15523074 (Pubitemid 39435104)
13. E Estey D Hoth R Simon S Marsoni B Leyland-Jones R Wittes 1996 Therapeutic responses in phase I trials of antineoplastic agents Cancer Treat Rep 70 1105 1115